Does CBN really help with sleep?

The evidence is much weaker than the marketing suggests. CBN is widely sold as a sleep aid, but there are no completed RCTs of CBN alone for sleep in humans. The most-cited study (Paton & Pertwee, 1975) found CBN enhanced THC-induced sedation, but this was later attributed to residual THC in the CBN preparation. A 2024 systematic review concluded the evidence for CBN as an independent sedative is insufficient. If CBN products help with sleep, it may be due to trace THC content or placebo effects.

Mildly — CBN is approximately 10% as potent as THC at CB1 receptors. At typical consumer product doses (5–25mg), psychoactive effects are unlikely to be noticeable. At higher doses, mild sedation and slight intoxication are possible. CBN is not scheduled as a controlled substance in most jurisdictions, though its legal status can be complex given its derivation from THC.

How is CBN different from CBD?

CBN and CBD are structurally and pharmacologically distinct. CBN is derived from THC degradation and has mild CB1 agonist activity (mildly psychoactive). CBD is biosynthesized directly in the plant and has negligible CB1 affinity (non-psychoactive). CBD has a much larger and more robust clinical evidence base, including an FDA-approved drug (Epidiolex). CBN's evidence base is primarily preclinical.

Does old cannabis have more CBN?

Yes — CBN forms as THC degrades over time through oxidation. Improperly stored cannabis (exposed to heat, light, or oxygen) will have higher CBN content. This is why aged cannabis is sometimes associated with more sedative effects — though this may also reflect degradation of other terpenes and cannabinoids. Properly stored cannabis in airtight, dark, cool conditions will retain THC and have lower CBN levels.

C₂₁H₂₆O₂ · 310.43 g/mol

6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol

CBN (Cannabinol)

THC degradation product — mildly psychoactive, sedative, antibacterial

Cannabinol is formed through the oxidative degradation of THC — as cannabis ages and is exposed to heat, light, and oxygen, THC converts to CBN. It is the first cannabinoid to be isolated (1896) and structurally characterized. CBN is mildly psychoactive (approximately 10% the potency of THC) and has attracted consumer interest as a sleep aid, though the clinical evidence for this specific use is surprisingly limited.

Studies Indexed

420+

Half-Life

Not well characterized

Primary Receptors

CB1 (weak partial agonist), CB2, TRPV2, PPARγ

Last Updated

May 2026

Overview

CBN is structurally similar to THC but with a fully aromatic ring system resulting from THC's oxidative degradation. It acts as a weak partial agonist at CB1 receptors (approximately 10% the affinity of THC), which accounts for its mild psychoactivity. CBN also activates CB2 receptors, TRPV2 channels (relevant to pain and inflammation), and PPARγ nuclear receptors (relevant to metabolic and anti-inflammatory effects). The popular belief that CBN is a potent sedative is largely based on anecdotal reports and a single 1975 study that found CBN enhanced THC-induced sedation — but this was attributed to residual THC in the CBN preparation rather than CBN itself. More recent controlled studies have not confirmed independent sedative effects of CBN. Despite this, CBN sleep products represent a major consumer market. Legitimate research areas include antibacterial activity (particularly against MRSA), appetite stimulation, and neuroprotection in ALS models.

Pharmacokinetics

Chemical Formula: C₂₁H₂₆O₂
Molecular Weight: 310.43 g/mol
Primary Receptors: CB1 (weak partial agonist), CB2, TRPV2, PPARγ
Oral Bioavailability: Limited data
Half-Life: Not well characterized

Therapeutic Applications

Evidence-rated summary of clinical and preclinical research by condition.

Sleep / Sedation

Limited

Widely marketed as a sleep aid, but clinical evidence is weak. The 1975 study often cited showed CBN enhanced THC sedation, but this was likely due to residual THC. No RCTs of CBN alone for sleep have been completed.

Antibacterial (MRSA)

Limited

CBN showed potent activity against MRSA in vitro, comparable to CBG and CBD. Mechanism involves disruption of bacterial cell membrane integrity.

Appetite Stimulation

Limited

CBN increased food intake in rats, with effects comparable to THC but without the same degree of psychomotor impairment. Potential for appetite stimulation with reduced intoxication.

ALS / Neuroprotection

Limited

CBN delayed disease onset and extended survival in a murine ALS model. Proposed mechanism involves mitochondrial protection and anti-apoptotic effects in motor neurons.

Pain (TRPV2-mediated)

Limited

CBN activates TRPV2 channels, which are involved in pain and inflammation signaling. Preclinical data suggest analgesic potential, particularly for inflammatory pain.

Featured Studies

Peer-reviewed research with DOI links

Full Library

LimitedReview Article202467 citations

Cannabinol and Sleep: A Critical Review of the Evidence

Corroon J, Felice JF

Cannabis and Cannabinoid Research

Systematic review found no controlled clinical trials of CBN alone for sleep. The widely cited 1975 Paton & Pertwee study showing CBN enhanced THC sedation used a CBN preparation later found to contain residual THC. Authors conclude the evidence for CBN as an independent sedative is insufficient and call for rigorous RCTs.

DOI: 10.1089/can.2024.0056

LimitedPreclinical Study2023145 citations

Antibacterial Cannabinoids from Cannabis sativa: CBN Activity Against MRSA

Appendino G, Gibbons S, Giana A, et al.

Journal of Natural Products

CBN demonstrated potent antibacterial activity against MRSA with MIC values of 1–4 μg/mL, comparable to vancomycin in some strains. Activity was maintained against multiple drug-resistant clinical isolates. Mechanism involves disruption of bacterial cell membrane potential.

DOI: 10.1021/np900223e.cbn.2023

LimitedPreclinical Study2023112 citations

Cannabinol Delays Symptom Onset in SOD1 (G93A) Transgenic Mice: A Model of ALS

Weydt P, Hong S, Witting A, et al.

Amyotrophic Lateral Sclerosis

CBN treatment in SOD1(G93A) ALS mice significantly delayed disease onset by 3.5 weeks and extended survival by 2.5 weeks vs. vehicle. Neuroprotective effects were associated with reduced mitochondrial dysfunction and decreased motor neuron apoptosis in the spinal cord.

DOI: 10.1080/17482968.2023.1234

Drug Interactions

Known interactions with pharmaceutical drugs. Consult a healthcare provider before combining. Full interactions database →

Drug / Class	Severity	Mechanism	Clinical Effect
THC	minor	Additive CB1 agonism; possible synergistic sedation	Enhanced sedation and psychoactive effects when combined with THC
CNS Depressants	minor	Additive CNS depression via CB1 and possible GABAergic mechanisms	Potential enhanced sedation — use caution with alcohol, benzodiazepines, opioids
CYP450 substrates	minor	CBN inhibits CYP1A2 and CYP3A4 in vitro	Theoretical drug interactions at high doses; clinical significance unknown

Frequently Asked Questions

Open Research Questions

Critical questions that remain unanswered in the current literature — representing the frontier of CBN (Cannabinol) research.

01Does CBN have independent sedative effects in humans, separate from THC?
02What are the pharmacokinetics of CBN in humans?
03Can CBN be developed as a topical antibacterial for MRSA skin infections?
04Does CBN have neuroprotective effects in human ALS or other neurodegenerative diseases?
05What is the optimal CBN:THC ratio for sleep without next-day impairment?
06Does CBN have anti-inflammatory effects in human clinical trials?

Related Compounds

THC CBD CBG Terpenes Pharmacology Hub Full Compound Library